MXPA05011524A - Acidos carboxilicos sustituidos. - Google Patents
Acidos carboxilicos sustituidos.Info
- Publication number
- MXPA05011524A MXPA05011524A MXPA05011524A MXPA05011524A MXPA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A
- Authority
- MX
- Mexico
- Prior art keywords
- useful
- compounds
- carboxylic acids
- treatment
- substituted carboxylic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente invencion se refiere a compuestos y sales farmaceuticamente aceptables de la formula (I): que son utiles en el tratamiento de trastornos metabolicos relacionados a resistencia a insulina e hiperglicemia. Estos compuestos incluyen inhibidores de la proteina tirosina-fosfatasa (PTP-1B) que son utiles en el tratamiento de diabetes y otras enfermedades mediadas por TPT-1B, tal como cancer, enfermedades neurodegenerativas y similares. Los compuestos de la invencion tambien son utiles en composiciones farmaceuticas y metodos de tratamiento de las condiciones mencionadas anteriormente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46705703P | 2003-04-30 | 2003-04-30 | |
PCT/US2004/011371 WO2004099168A2 (en) | 2003-04-30 | 2004-04-14 | Substituted carboxylic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05011524A true MXPA05011524A (es) | 2006-03-21 |
Family
ID=33435014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05011524A MXPA05011524A (es) | 2003-04-30 | 2004-04-14 | Acidos carboxilicos sustituidos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US7358364B2 (es) |
EP (1) | EP1620420A2 (es) |
JP (1) | JP2006525329A (es) |
KR (1) | KR20060006953A (es) |
CN (1) | CN1812977A (es) |
AU (1) | AU2004236173B2 (es) |
BR (1) | BRPI0409914A (es) |
CA (1) | CA2523714A1 (es) |
EA (1) | EA200501710A1 (es) |
MX (1) | MXPA05011524A (es) |
NO (1) | NO20054957L (es) |
WO (1) | WO2004099168A2 (es) |
ZA (1) | ZA200509631B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200501710A1 (ru) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые карбоновые кислоты |
US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
FR2869615B1 (fr) * | 2004-05-03 | 2007-11-16 | Merck Sante Soc Par Actions Si | Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
KR20070083484A (ko) | 2004-07-14 | 2007-08-24 | 피티씨 테라퓨틱스, 인크. | C형 간염 치료 방법 |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
AU2005275182A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating Hepatitis C |
JP2008518937A (ja) * | 2004-10-28 | 2008-06-05 | ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換カルボン酸 |
AU2005307718A1 (en) * | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
NZ571835A (en) | 2006-03-29 | 2011-11-25 | Velacor Therapeutics Pty Ltd | Treatment of neurodegenerative diseases |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
CA2686838C (en) | 2007-05-09 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
PT2639222T (pt) | 2007-12-07 | 2016-11-01 | Vertex Pharma | Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
RU2538964C1 (ru) | 2010-12-17 | 2015-01-10 | Мицубиси Танабе Фарма Корпорейшн | Соединение с последовательной арициклической структурой, обладающее активностью ингибирования ацилкофермента а: диацилглицеринацилтрансферазы (dgat1) |
EP2862856B1 (en) | 2012-06-15 | 2018-08-01 | Mitsubishi Tanabe Pharma Corporation | Imidazole and triazole compounds as dgat-1 inhibitors |
EA201690152A1 (ru) * | 2013-07-11 | 2016-05-31 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
PL3068392T3 (pl) | 2013-11-12 | 2021-07-19 | Vertex Pharmaceuticals Incorporated | Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr |
WO2015150362A2 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
CN106661008A (zh) | 2014-04-03 | 2017-05-10 | 拜耳制药股份公司 | 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸 |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
EP3247770B1 (de) * | 2015-01-20 | 2019-04-10 | cynora GmbH | Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1176339A (en) * | 1965-12-27 | 1970-01-01 | Lilly Co Eli | Hydrocinnamic Acid Compounds and Processes for making them |
IL30498A0 (en) | 1967-08-14 | 1968-10-24 | Merck & Co Inc | Process for the preparation of phenyl salicylic acid compounds and intermediates used therein |
CH542806A (de) * | 1967-10-06 | 1973-10-15 | Ciba Geigy Ag | Verfahren zur Herstellung einer neuen Aryloxyalkansäure und ihrer Salze |
CH499526A (de) * | 1968-06-06 | 1970-11-30 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Tetrazolderivaten |
US3755603A (en) | 1970-07-01 | 1973-08-28 | Syntex Corp | Biphenylyloxyacetic acids in pharmaceutical compositions |
DE2205732A1 (de) | 1972-02-08 | 1973-08-16 | Thomae Gmbh Dr K | Neue 4-(4-biphenylyl)-butensaeurederivate |
NL7301246A (es) * | 1972-02-14 | 1973-08-16 | ||
DE2358789A1 (de) * | 1973-02-07 | 1975-06-05 | Merck Patent Gmbh | Hydratropasaeure-derivate und verfahren zu ihrer herstellung |
FR2457275A1 (fr) | 1979-05-21 | 1980-12-19 | Fabre Sa Pierre | Acides p-biphenyl-4 methyl-2 buten-3 oiques utiles dans le traitement des rhumatismes |
TW268952B (es) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
US5886022A (en) | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
JP3628335B2 (ja) | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
CA2249009C (en) | 1996-04-12 | 2003-09-16 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
WO1997039748A1 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
IT1290679B1 (it) * | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
AU8750298A (en) | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
PE20000127A1 (es) | 1997-12-22 | 2000-03-14 | Novartis Ag | Derivado de bencenosulfonamida |
WO1999046236A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
US6214991B1 (en) | 1998-03-31 | 2001-04-10 | The Institute For Pharmaceutical Discovery, Inc. | Substituted indolealkanoic acids |
JP2002514635A (ja) * | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン耐性および高血糖の処置に有用なビフェニルオキソ−酢酸 |
ATE228120T1 (de) | 1998-05-12 | 2002-12-15 | Wyeth Corp | Biphenylsulfonylarylcarbonsäuren verwendbar zur behandlung von insulin resistenz und hyperglycemia |
US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
JP2002516305A (ja) | 1998-05-12 | 2002-06-04 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン抵抗性および高血糖症の治療に有用な2,3,5−置換ビフェニル |
US6221902B1 (en) * | 1998-05-12 | 2001-04-24 | American Home Products Corporation | Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
CA2330558A1 (en) | 1998-05-12 | 1999-11-18 | Wyeth | (2-acylaminothiazole-4-yl)acetic acid derivatives |
HUP0201291A3 (en) | 1999-04-28 | 2002-11-28 | Sanofi Aventis Deutschland | Di-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them |
BR0011928A (pt) | 1999-06-25 | 2002-04-09 | Inst For Pharm Discovery Inc | Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética |
EP1268495A1 (en) | 2000-03-22 | 2003-01-02 | Merck Frosst Canada Inc. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
WO2001083464A1 (fr) | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire |
AU2001248820A1 (en) | 2000-04-28 | 2001-11-12 | Shionogi And Co., Ltd. | Thiazole and oxazole derivatives |
AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
JP2004502775A (ja) | 2000-07-07 | 2004-01-29 | ノボ ノルディスク アクティーゼルスカブ | 非ヌクレオシド逆転写阻害剤抗レトロウイルス療法をモニターするための手段および方法 |
WO2002008188A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
US6472545B2 (en) | 2000-08-29 | 2002-10-29 | Abbott Laboratories | Protein tyrosine phosphatase inhibitors |
CA2423885A1 (en) | 2000-09-29 | 2003-03-27 | Shionogi & Co., Ltd. | Thiazole and oxazole derivatives |
EP1366012A4 (en) | 2001-02-09 | 2005-11-02 | Merck & Co Inc | 2-ARYLOXY-2-ARYLALCANO ACIDS AS USED FOR THE TREATMENT OF DIAB TES AND LIPID DISORDERS |
MXPA03011558A (es) | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
DE10150172A1 (de) | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
JP4219810B2 (ja) | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Mmp阻害作用を有するスルホンアミド誘導体 |
WO2003048140A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
DE60332738D1 (de) | 2002-07-30 | 2010-07-08 | Merck Sharp & Dohme | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen |
BR0313825A (pt) | 2002-08-29 | 2005-07-12 | Merck & Co Inc | Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto |
CN1794989A (zh) | 2003-04-14 | 2006-06-28 | 药物研发有限责任公司 | 用于治疗糖尿病的n-(((((1,3-噻唑-2-基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物 |
EA200501710A1 (ru) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые карбоновые кислоты |
JPWO2005063222A1 (ja) | 2003-12-26 | 2007-07-19 | 協和醗酵工業株式会社 | Hsp90ファミリー蛋白質阻害剤 |
JP2008518926A (ja) | 2004-10-28 | 2008-06-05 | ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換フェニルアルカン酸 |
-
2004
- 2004-04-14 EA EA200501710A patent/EA200501710A1/ru unknown
- 2004-04-14 US US10/823,842 patent/US7358364B2/en not_active Expired - Fee Related
- 2004-04-14 JP JP2006509981A patent/JP2006525329A/ja active Pending
- 2004-04-14 EP EP04760538A patent/EP1620420A2/en not_active Withdrawn
- 2004-04-14 WO PCT/US2004/011371 patent/WO2004099168A2/en active Application Filing
- 2004-04-14 MX MXPA05011524A patent/MXPA05011524A/es not_active Application Discontinuation
- 2004-04-14 BR BRPI0409914-1A patent/BRPI0409914A/pt not_active IP Right Cessation
- 2004-04-14 CA CA002523714A patent/CA2523714A1/en not_active Abandoned
- 2004-04-14 AU AU2004236173A patent/AU2004236173B2/en not_active Ceased
- 2004-04-14 CN CNA2004800184160A patent/CN1812977A/zh active Pending
- 2004-04-14 KR KR1020057020613A patent/KR20060006953A/ko not_active Application Discontinuation
-
2005
- 2005-10-25 NO NO20054957A patent/NO20054957L/no not_active Application Discontinuation
- 2005-11-29 ZA ZA200509631A patent/ZA200509631B/en unknown
-
2008
- 2008-04-15 US US12/103,082 patent/US20090082392A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090082392A1 (en) | 2009-03-26 |
JP2006525329A (ja) | 2006-11-09 |
AU2004236173B2 (en) | 2008-07-03 |
EA200501710A1 (ru) | 2006-06-30 |
BRPI0409914A (pt) | 2006-04-25 |
EP1620420A2 (en) | 2006-02-01 |
WO2004099168A2 (en) | 2004-11-18 |
WO2004099168A3 (en) | 2005-02-24 |
US20040266788A1 (en) | 2004-12-30 |
NO20054957L (no) | 2006-01-23 |
ZA200509631B (en) | 2007-02-28 |
US7358364B2 (en) | 2008-04-15 |
CA2523714A1 (en) | 2004-11-18 |
CN1812977A (zh) | 2006-08-02 |
AU2004236173A1 (en) | 2004-11-18 |
NO20054957D0 (no) | 2005-10-25 |
KR20060006953A (ko) | 2006-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
TW200630327A (en) | Substituted phenylalkanoic acids | |
MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
RS20050814A (en) | Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b | |
MXPA05011536A (es) | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. | |
TW200630354A (en) | Substituted amino carboxylic acids | |
WO2006055708A3 (en) | Heterocycle substituted carboxylic acids for the treatment of diabetes | |
MXPA05011523A (es) | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. | |
WO2006055625A3 (en) | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors | |
WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
WO2008033932A3 (en) | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors | |
WO2008033455A3 (en) | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors | |
EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
IL192557A (en) | Imidazole derivatives are conserved and used as ptpase inhibitors | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
TW200631949A (en) | Substituted carboxylic acids | |
WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
HK1079526A1 (en) | A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin | |
DE602005007912D1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
WO2006138589A3 (en) | Opioid receptor ligands | |
DE602004013770D1 (de) | Diagnostik- und therapie- verfahren von mit pils verbundenen krankheiten | |
ATE397755T1 (de) | Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |